StockData
Editas Medicine, Inc. logo

Editas Medicine, Inc. (EDIT) stock

EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/309% above fair value
$1.77−0.05 (-3.01%)

Close on Nov 18, 2026Market cap $271.84MP/E –Yield –

Editas Medicine gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Editas Medicine

Editas Medicine has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Editas Medicine figures

See a number that looks wrong?